Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/18/22
Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022GlobeNewsWire • 02/11/22
Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/22
Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development OfficerGlobeNewsWire • 12/17/21
Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/09/21
Coherus BioSciences (CHRS) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/09/21
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022GlobeNewsWire • 11/05/21
Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8thGlobeNewsWire • 10/29/21
Earnings Preview: Coherus BioSciences (CHRS) Q3 Earnings Expected to DeclineZacks Investment Research • 10/28/21
Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical TrialGlobeNewsWire • 10/05/21
Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for ReviewGlobeNewsWire • 10/01/21